These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 439883)

  • 1. Exchange of plasminogen activator between solution and intima.
    Gall W; Gurll NJ; Wright CB; Reynolds DG
    J Surg Res; 1979 May; 26(5):523-7. PubMed ID: 439883
    [No Abstract]   [Full Text] [Related]  

  • 2. High-dose, short-term local urokinase for clearing femoral thrombi by vasodilation and thrombolysis.
    Gurll NJ; Callahan W; Hufnagel HV
    J Surg Res; 1976 May; 20(5):381-8. PubMed ID: 933494
    [No Abstract]   [Full Text] [Related]  

  • 3. Differences in the reactivities of human urokinase and the porcine tissue plasminogen activator.
    Thorsen S; Astrup T
    Haemostasis; 1976; 5(5):295-305. PubMed ID: 14058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vasodilation, fibrinolysis, and thrombolysis with intraarterial infusion of urokinase in the canine superior mesenteric artery.
    Gurll N; Zinner MJ; Turtinen L; Reynolds DG
    Gastroenterology; 1978 Sep; 75(3):425-31. PubMed ID: 98390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative study of different urokinase preparations.
    Millar WT; Smith JF
    Thromb Res; 1983 Jun; 30(5):425-9. PubMed ID: 6351343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Some aspects of the dose-response relation in urokinase administration.
    Matsuo O; Rokushima Y
    Thromb Res; 1976 May; 8(2 suppl):97-106. PubMed ID: 936100
    [No Abstract]   [Full Text] [Related]  

  • 7. Bolus dose response characteristics of single chain urokinase plasminogen activator and tissue plasminogen activator in a dog model of arterial thrombosis.
    Badylak SF; Voytik S; Klabunde RE; Henkin J; Leski M
    Thromb Res; 1988 Nov; 52(4):295-312. PubMed ID: 3144052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of IUD on urokinase-like immunoreactivity and plasminogen activators in human uterine fluid.
    Casslén B; Thorell J; Astedt B
    Contraception; 1981 Apr; 23(4):435-45. PubMed ID: 7023822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The biphasic nature and temperature dependence of the activation of human plasminogen by urokinase. A simple urokinase assay based on this phenomenon.
    Ambrus CM; Bartfay-Szabo A; Mirand E; Ambrus JL
    Res Commun Chem Pathol Pharmacol; 1979 May; 24(2):339-47. PubMed ID: 461988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Activation of plasminogen and prothrombin by immobilized activators -- urokinase and thromboplastin (author's transl)].
    Rybák M; Coupek J
    Cas Lek Cesk; 1980 Oct; 119(40-41):1106-8. PubMed ID: 7026035
    [No Abstract]   [Full Text] [Related]  

  • 11. Expression of the catalytic activity of plasminogen activator under physiologic conditions.
    Aggeler J; Risch J; Werb Z
    Biochim Biophys Acta; 1981 Jun; 675(1):62-8. PubMed ID: 6455162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Studies on a plasminogen activating system in human milk: IV. Difference in the binding to fibrin between human milk plasminogen activator (mild activator) and urokinase (author's transl)].
    Horie N
    Nihon Ketsueki Gakkai Zasshi; 1979 Oct; 42(5):38-45. PubMed ID: 396753
    [No Abstract]   [Full Text] [Related]  

  • 13. Comparative thrombolytic properties of tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (u-PA) and K1K2Pu (a t-PA/u-PA chimera) in a combined arterial and venous thrombosis model in the dog.
    Lu HR; Wu Z; Pauwels P; Lijnen HR; Collen D
    J Am Coll Cardiol; 1992 May; 19(6):1350-9. PubMed ID: 1342779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasminogen activator and proactivator (urokinase precursor) in lung cultures.
    Bernik MB; Oller EP
    J Am Med Womens Assoc (1972); 1976 Dec; 31(12):465-72. PubMed ID: 186502
    [No Abstract]   [Full Text] [Related]  

  • 15. Inhibitory effect of amidino-substituted heterocyclic compounds on the amidase activity of plasmin and of high and low molecular weight urokinase and on urokinase-induced plasminogen activation.
    Geratz JD; Shaver SR; Tidwell RR
    Thromb Res; 1981 Oct 1-15; 24(1-2):73-83. PubMed ID: 6460342
    [No Abstract]   [Full Text] [Related]  

  • 16. Vasodilation due to urokinase in the canine femoral circulation.
    Gurll NJ; Zinner MJ; Callahan W; Reynolds DG
    J Pharmacol Exp Ther; 1977 Jun; 201(3):731-7. PubMed ID: 864605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The plasminogen activator and esterase activities of the two forms of urokinase.
    Ong EB; Soberano ME; Johnson AJ; Dharmgrongartama ED
    Thromb Res; 1981 Nov; 24(3):223-32. PubMed ID: 7038974
    [No Abstract]   [Full Text] [Related]  

  • 18. Human urokinase and porcine tissue plasminogen activator. A comparative study of the mechanism of fibrinolysis, and the effect of natural proteinase inhibitors and omega-aminocarboxylic acids.
    Thorsen S
    Dan Med Bull; 1977 Oct; 24(5):189-206. PubMed ID: 908205
    [No Abstract]   [Full Text] [Related]  

  • 19. Purification and characterization of human kidney plasminogen activator dissimilar to urokinase.
    Sueishi K; Nanno S; Okamura T; Inoue S; Tanaka K
    Biochim Biophys Acta; 1982 Aug; 717(2):327-36. PubMed ID: 7052141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancement of urokinase-induced plasminogen activation by the cationic protein of human eosinophil granulocytes.
    Dahl R; Venge P
    Thromb Res; 1979; 14(4-5):599-608. PubMed ID: 483258
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.